• Travere Therapeutics Chief Medical Officer Jula Inrig reported sales of 22,485 shares on May 4-6 at prices ranging from USD 43.95 to USD 46.65.
• Transaction included exercise of 20,000 employee stock options at USD 22.4, followed by sale of 20,000 shares at USD 45 on May 4.
• Holdings ended at 113,238 shares of common stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001902368-26-000006), on May 06, 2026, and is solely responsible for the information contained therein.